Oruka Therapeutics Announces Positive Week 28 Data For Orka-001 From The Ongoing Everlast-A Trial Showing Deepening Of Responses Without Additional Dosing
ORKA•ORKA•ORKA•ORKA•Oruka Therapeutics said two serious adverse events were reported, and neither was deemed drug-related.
The company said 16-week Everlast-B data are expected in the fourth quarter of 2026, and 52-week Everlast-A data are expected in December 2026.
Oruka Therapeutics Inc. said positive Week 28 data for Orka-001 from the ongoing Everlast-A trial showed deepening of responses without additional dosing.
The company said Orka-001 maintained a favorable safety and tolerability profile through Week 28.
